An iron complex based on 5-fluoro-4-hydrazinyl-2-methoxypyrimidine and synthesis and application thereof
By designing a double-ligand sandwich Fe^II complex based on 5-fluoro-4-hydrazino-2-methoxypyrimidine, the problem of insufficient stability of iron complexes in the physiological environment was solved, and effective inhibition and chemotherapy effects on TNBC cells were achieved.
Patent Information
- Application Number
- CN202610849012.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-06-12
- Publication Date
- 2026-07-17
AI Technical Summary
Existing technologies have difficulty effectively utilizing the stability of iron complexes in physiological environments, which limits their therapeutic efficacy in treating triple-negative breast cancer (TNBC). In particular, the instability of Fe^II complexes under physiological conditions affects their accumulation and anti-tumor activity in TNBC cells.
A double-ligand sandwich Fe^II complex based on 5-fluoro-4-hydrazino-2-methoxypyrimidine was designed and synthesized. The complex was formed by condensation with an aromatic aldehyde to form ligand L and then reacted in the presence of an acid catalyst to generate a physiologically stable iron complex that promotes the accumulation of Fe^II in TNBC cells.
The iron complex was stabilized under physiological conditions, which increased the accumulation of FeII in TNBC cells, promoted ferroptosis, enhanced the inhibitory effect on TNBC cells, and showed good safety and chemotherapeutic effect.
Smart Images
Figure CN122404236A_ABST